TYGACIL (tigecycline) is a glycylcycline antibacterial for intravenous infusion. The chemical name of tigecycline is (4 S,4a S,5a R,12a S)-9-[2-(tert -butylamino)acetamido]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
TYGACIL is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:
Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and ‑resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes and Bacteroides fragilis.
Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus) , Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros.
Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to tigecycline. TYGACIL may be initiated as empiric monotherapy before results of these tests are known.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Published Studies Related to Tygacil (Tigecycline)
Tigecycline for the treatment of severe Clostridium difficile infection. [2011.07]
CONCLUSIONS: Case reports have suggested that tigecycline may be successful for treatment of severe or severe complicated CDI, when prior therapy has failed. Data demonstrating tigecycline use as initial therapy for CDI are limited; therefore, this option should be reserved for patients in whom other therapeutic options, including metronidazole and vancomycin, have failed. A randomized controlled trial is needed to assess the safety and efficacy of tigecycline in this patient population and better define the drug's role in the treatment of CDI.
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. [2011.04]
BACKGROUND: To compare the monotherapy of tigecycline with vancomycin-aztreonam in hospitalized patients from India and Taiwan with complicated skin and skin structure infections (cSSSIs)... CONCLUSIONS: Tigecycline monotherapy is a safe and effective therapy for cSSSIs in geographically distinct populations in Asia. Copyright (c) 2011. Published by Elsevier B.V.
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam
in the treatment of complicated skin and skin structure infections in patients
from India and Taiwan. 
structure infections (cSSSIs)... CONCLUSIONS: Tigecycline monotherapy is a safe and effective therapy for cSSSIs
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. [2010.12]
Tigecycline is a new-generation of tetracycline (glycylcyclines) and is active in vitro against bacteria that possess any of the classical genes that confer tetracycline resistance through ribosomal protection or efflux pumps. Herein, tigecycline disposition in patients with community- or hospital-acquired pneumonia was described using a population pharmacokinetic model...
Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. [2010.07.21]
BACKGROUND: Tigecycline, a first-in-class broad-spectrum glycylcycline antibiotic, has broad-spectrum in vitro activity against bacteria commonly encountered in complicated intra-abdominal infections (cIAIs), including aerobic and facultative Gram-positive and Gram-negative bacteria and anaerobic bacteria. In the current trial, tigecycline was evaluated for safety and efficacy vs. imipenem/cilastatin in hospitalized Chinese patients with cIAIs... CONCLUSIONS: Clinical cure rates for tigecycline were consistent with those found in global cIAI studies. The overall safety profile was also consistent with that observed in global studies of tigecycline for treatment of cIAI, as well as that observed in analyses of Chinese patients in those studies; no novel trends were observed. TRIAL REGISTRATION: ClinicalTrials.gov NCT00136201.
Clinical Trials Related to Tygacil (Tigecycline)
Post-Marketing Study of the Safety of Tygacil (Tigecycline) [Recruiting]
Effectiveness and Safety of Tigecycline for Therapy of Infections Caused by Multi-Drug Resistant Acinetobacter Baumannii [Recruiting]
30 adult hospitalized patients who have infections due to MDR Acinetobacter baumannii will
be enrolled. The eligible patients will receive 100 mg of tigecycline intravenous infusion
for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days. Clinical outcomes on
effectiveness and safety will be evaluated on daily basis up to 28 days. Follow-up culture
of clinical specimen from the site of infection will be obtained on day 3 and at the end of
tigecycline therapy. Clinical response is classified as cure, improvement, failure, relapse,
death. Microbiological outcome is assessed at the end of treatment and classified as
eradication, persistence, colonization, and superinfection. Adverse events, overall 28-day
mortality and infection-related mortality will be determined. Length of stay will also be
Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia [Recruiting]
This study will compare the safety and efficacy of a tigecycline regimen versus an
imipenem/cilastatin regimen for the treatment of subjects who are hospitalized with
hospital-acquired pneumonia (HAP). At least 70% of enrolled subjects will have
ventilator-associated pneumonia (VAP). Two dose levels of tigecycline will be assessed and
compared to imipenem/cilastatin in parallel. Subjects will receive intravenous therapy from
a minimum of 7 & up to 14 consecutive days, the exact duration will be at the decision of
the investigator based on the subject's condition. Additional protocol specified antibiotics
may be given to ensure appropriate coverage. A final assessment at test-of-cure (TOC) visit
will be done 10 to 21 days after the last day of therapy. The total duration of subject
participation will be between 17 and 44 days, including a follow up period of 30 days after
the last day of therapy for SAEs.
Subjects will be followed for safety and efficacy. The safety assessment will include:
physical examinations, vital signs, assessment of the clinical signs and symptoms of
pneumonia, collection of adverse events, 12-lead ECG, collection of samples for hematology,
serum chemistries, and coagulation parameters, & a serum or urine pregnancy test before
study entry for women of childbearing potential. The clinical and microbiological efficacy
will both be evaluated.
Safety and Efficacy of Tigecycline in the Treatment of C. Difficile Associated Diarrhea(CDAD) [Recruiting]
This is a prospective, non-comparative, interventional, observational pilot study of the
safety and efficacy of intravenous (IV) tigecycline in conjunction with standard therapy in
patients with known mild to severe confirmed C. Difficile Associated Diarrhea (CDAD).
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia [Recruiting]
The purpose of this study is to determine whether tigecycline is safe and which dosage is
most effective in the treatment of patients with acute myeloid leukemia.
Reports of Suspected Tygacil (Tigecycline) Side Effects
Drug Ineffective (7),
Adverse Drug Reaction (4),
Impaired Work Ability (4),
Pulmonary Oedema (4), more >>
Page last updated: 2013-02-10